14.76

0.61% -0.09

After Hours: 14.75 -0.010 -0.07%

Greenwich LifeSciences Inc (GLSI)

Overview News Price History Financials Discussions Forecast

Greenwich LifeSciences Inc stock is currently priced at $14.76, with a 24-hour trading volume of 17,200. It has seen a -0.61% decreased in the last 24 hours and a +8.21% rose in the past month. The chart indicates a potential bullish trend, as the stock is above the $14.65 pivot point. If it approaches the $15.05 resistance level, significant changes may occur.

Previous Close:

$14.85

Open:

$15

24h Volume:

17,200

Market Cap:

$190.11M

Revenue:

Net Income/Loss:

$-8.89M

P/E Ratio:

-21.09

EPS:

-0.7

Net Cash Flow:

$-6.48M

1W Performance:

+2.64%

1M Performance:

+8.21%

6M Performance:

+36.04%

1Y Performance:

+32.50%

1D Range:

$14.57

$15.47

52W Range:

$7.58

$21.44

Greenwich LifeSciences Inc Stock (GLSI) Company Profile

Name

Greenwich LifeSciences Inc

Sector

Healthcare (1204)

Industry

Biotechnology (696)

Phone

832-819-3232

Address

Building 14, 3992 Bluebonnet Drive, Stafford

Employee

Twitter

Next Earnings Date

2024-05-22

Latest SEC Filings

GLSI's Discussions on Twitter

Greenwich LifeSciences Inc Stock (GLSI) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-01-21	Initiated	H.C. Wainwright	Buy

Greenwich LifeSciences Inc Stock (GLSI) Latest News

Greenwich CEO buys shares in private placement By Investing.com - Investing.com

Investing.com

Greenwich LifeSciences Announces $2.5 Million Private Placement | $GLSI Stock News - StockTitan

StockTitan

Greenwich LifeSciences Inc Stock (GLSI) Financials Data

Greenwich LifeSciences Inc (GLSI) Net Income 2024

GLSI net income (TTM) was -$8.89 million for the quarter ending December 31, 2023, a -13.63% decrease year-over-year.

Greenwich LifeSciences Inc (GLSI) Cash Flow 2024

GLSI recorded a free cash flow (TTM) of -$6.48 million for the quarter ending December 31, 2023, a -4.49% decrease year-over-year.

Greenwich LifeSciences Inc (GLSI) Earnings per Share 2024

GLSI earnings per share (TTM) was -$0.70 for the quarter ending December 31, 2023, a -14.75% decline year-over-year.

Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of cancer immunotherapies for breast cancer and other human epidermal growth factor receptor 2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent recurrence of breast cancer following surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was founded in 2006 and is based in Stafford, Texas.